Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NIO Inc. (NIO) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

NIO Inc. vs Novavax Inc — how do they compare? NIO Inc. trades at $4.54 (market cap $11.59B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: NIO Inc. is far larger — about 8.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.

NIONVAX
Market Cap
$11.59B$1.31B
Sector
Consumer CyclicalHealth
52-Week High
$7.89$11.19
52-Week Low
$4.44$6.22
Enterprise Value
$10.82B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NIO Inc.

NIO's stock trades at $4.575, down 5.08% amid bearish technical signals and negative cash flows. Revenue grew to $87.49 billion in 2025, but net losses persist at -$15.57 billion. Recent news highlights delivery growth and competitive pressures in China's EV market, with shares near support levels after a steep decline from 2026 highs.

The outlook remains challenged by profitability concerns and high debt, though analyst consensus leans bullish with 54% buy ratings. Key risks include intense competition and reliance on financing, while potential upside hinges on margin improvement and sustained delivery growth in a volatile sector.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NIO Inc.

NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.

Read more on NIO

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX